Bokhari Raza 4

What Happened
Bokhari Raza, Chief Executive Officer of Medicus Pharma Ltd. (MDCX), was reported on a Form 4 as receiving a 325,000-share award on March 30, 2026. The filing lists the acquisition as a derivative award (transaction code A) with an acquisition price of $0.00—i.e., this was a grant/award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-03-30; Form 4 filed: 2026-04-01 (appears timely under the two-business-day rule).
• Transaction type/code: Award/Grant (A); derivative security.
• Shares acquired: 325,000; reported acquisition price: $0.00 (per the filing).
• Shares owned after the transaction: not disclosed in the excerpt provided.
• No 10b5-1, tax‑withholding or cashless sale notes included in the provided data.

Context

• Code A awards typically represent restricted stock, restricted stock units (RSUs), or other executive grants; such awards are recorded at $0 in many Form 4s even though the shares have market value.
• Awards are different from open‑market buys (which can signal personal conviction) and sales (which often fund taxes or diversification). An award is compensation-related and does not necessarily reflect immediate trading intent.
• The filing shows no indication of an immediate sale or cashless exercise tied to this award in the provided details.